Medtronic PLC (MDT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $131.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medtronic PLC (MDT) Financials: Revenue, Profit and Cash Flow
Medtronic reported revenue of $36.36B for the fiscal year ended Apr 30, 2026, up 8.4% from the year before. That year, net income was $4.84B with a net margin of 13.3%, operating cash flow was $7.33B and free cash flow was $5.43B. The quarter ended Jul 31, 2026 had revenue of $9.76B and net income of $1.48B.
Revenue and Margins
The operating margin was 17.8% in the fiscal year ended Apr 2026. Over the 9 years to Apr 2026, revenue grew from $29.71B, a compound annual rate of 2.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Apr 2026 | $36.36B | +8.4% | 65.0% | 17.8% | 13.3% |
| Apr 2025 | $33.54B | +3.6% | 65.3% | 17.8% | 14.0% |
| Apr 2024 | $32.36B | +3.6% | 65.3% | 15.9% | 11.4% |
| Apr 2023 | $31.23B | -1.4% | 65.7% | 17.6% | 12.1% |
| Apr 2022 | $31.69B | +5.2% | 68.0% | 18.2% | 16.0% |
| Apr 2021 | $30.12B | +4.2% | 65.2% | 14.9% | 12.1% |
| Apr 2020 | $28.91B | -5.4% | 67.4% | 16.6% | 16.6% |
| Apr 2019 | $30.56B | +2.0% | 70.0% | 20.5% | 15.2% |
| Apr 2018 | $29.95B | +0.8% | 69.7% | 22.2% | 10.3% |
| Apr 2017 | $29.71B | N/A | 68.7% | 18.1% | 13.5% |
Income Statement
In the fiscal year ended Apr 2026, net income rose 3.2% from the year before. In the quarter ended Jul 2026, net income rose 41.0% from the same quarter a year earlier.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B |
| Cost of revenue | $12.72B | $11.63B | $11.22B | $10.72B | $10.14B | $10.48B | $9.42B | $9.15B | $9.07B | $9.29B |
| Gross profit | $23.64B | $21.91B | $21.15B | $20.51B | $21.54B | $19.63B | $19.49B | $21.40B | $20.89B | $20.42B |
| Research and development | $2.87B | $2.73B | $2.73B | $2.70B | $2.75B | $2.49B | $2.33B | $2.33B | $2.26B | $2.19B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.64B | $5.38B |
| Net income | $4.84B | $4.69B | $3.71B | $3.78B | $5.06B | $3.63B | $4.81B | $4.65B | $3.10B | $4.02B |
| EBITDA | $9.81B | $9.22B | $8.20B | $8.70B | $8.78B | $7.52B | $7.81B | $9.30B | $9.46B | $8.61B |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.76B | $9.81B | $9.02B | $8.96B | $8.58B | $8.93B | $8.29B | $8.40B | $7.92B | $8.59B | $8.09B | $7.98B |
| Gross profit | $6.34B | $6.41B | $5.76B | $5.90B | $5.58B | $5.78B | $5.51B | $5.46B | $5.15B | $5.54B | $5.31B | $5.22B |
| Operating income | $1.76B | $1.87B | $1.46B | $1.69B | $1.45B | $1.44B | $1.65B | $1.59B | $1.28B | $1.05B | $1.48B | $1.34B |
| Net income | $1.48B | $1.26B | $1.15B | $1.38B | $1.05B | $1.06B | $1.30B | $1.28B | $1.05B | $660.00M | $1.34B | $911.00M |
Balance Sheet
As of Apr 2026, total debt of $27.96B exceeded cash and equivalents by $26.01B.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $93.03B | $91.68B | $89.98B | $90.95B | $90.98B | $93.08B | $90.69B | $89.69B | $91.39B | $99.86B |
| Current assets | $24.79B | $23.81B | $21.93B | $21.68B | $23.06B | $22.55B | $22.03B | $21.97B | $22.98B | $24.87B |
| Cash and equivalents | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B | $3.59B | $4.14B | $4.39B | $3.67B | $4.97B |
| Total liabilities | $42.96B | $43.42B | $39.56B | $39.28B | $38.26B | $41.48B | $39.82B | $39.48B | $40.57B | $49.53B |
| Short-term debt | $1.79B | $2.87B | $1.09B | $20.00M | $3.74B | $11.00M | $2.78B | $838.00M | $2.06B | $7.52B |
| Long-term debt | $26.17B | $25.64B | $23.93B | $24.34B | $20.37B | $26.38B | $22.02B | $24.49B | $23.70B | $25.92B |
| Shareholder equity | $49.46B | $48.02B | $50.21B | $51.48B | $52.55B | $51.43B | $50.74B | $50.09B | $50.72B | $50.21B |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B | $89.97B | $90.04B | $89.75B | $89.98B | $90.84B | $90.09B |
| Total liabilities | $42.46B | $42.96B | $42.29B | $42.49B | $42.84B | $43.42B | $40.36B | $41.33B | $41.59B | $39.56B | $38.84B | $38.44B |
| Cash and equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B | $1.24B | $1.39B | $1.31B | $1.28B | $1.62B | $1.31B |
| Shareholder equity | $50.23B | $49.46B | $48.98B | $48.65B | $47.89B | $48.02B | $49.39B | $48.49B | $47.95B | $50.21B | $51.79B | $51.46B |
Cash Flow
In the fiscal year ended Apr 2026, free cash flow was 74.1% of operating cash flow. Dividends and share repurchases together came to 86.0% of it.
Annual
| Line item | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B | $6.24B | $7.23B | $7.01B | $4.68B | $6.88B |
| Capital expenditures | $1.90B | $1.86B | $1.59B | $1.46B | $1.37B | $1.35B | $1.21B | $1.13B | $1.07B | $1.25B |
| Free cash flow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B | $4.88B | $6.02B | $5.87B | $3.62B | $5.63B |
| Dividends paid | $3.64B | $3.59B | $3.67B | $3.62B | $3.38B | $3.12B | $2.89B | $2.69B | $2.49B | $2.38B |
| Share repurchases | $1.03B | $3.23B | $2.14B | $645.00M | $2.54B | $652.00M | $1.33B | $2.88B | $2.17B | $3.54B |
| Investing cash flow | -$2.93B | -$1.94B | -$2.37B | -$3.49B | -$1.66B | -$2.87B | -$3.20B | -$774.00M | $5.86B | -$1.57B |
| Financing cash flow | -$4.75B | -$4.36B | -$4.45B | -$4.96B | -$5.34B | -$4.14B | -$4.20B | -$5.43B | -$11.95B | -$3.28B |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.79B | $2.57B | $2.74B | $925.00M | $1.09B | $2.53B | $2.57B | $958.00M | $986.00M | $2.78B | $2.47B | $661.00M |
| Capital expenditures | $503.00M | $488.00M | $444.00M | $468.00M | $504.00M | $459.00M | $476.00M | $404.00M | $520.00M | $426.00M | $346.00M | $461.00M |
| Free cash flow | $1.29B | $2.08B | $2.30B | $457.00M | $584.00M | $2.07B | $2.10B | $554.00M | $466.00M | $2.35B | $2.13B | $200.00M |
Frequently Asked Questions About MDT
What is Medtronic's annual revenue?
Medtronic reported revenue of $36.36B for the fiscal year ended Apr 30, 2026.
How fast is Medtronic's revenue growing?
Revenue was up 8.4% for the fiscal year ended Apr 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 5.2%.
Is Medtronic profitable?
Yes. Medtronic reported net income of $4.84B for the fiscal year ended Apr 30, 2026, with a net margin of 13.3%.
How much free cash flow does MDT generate?
For the fiscal year ended Apr 30, 2026, operating cash flow of $7.33B minus capital expenditures of $1.90B produced free cash flow of $5.43B.
How much debt does Medtronic have?
The balance sheet dated Apr 30, 2026 reported long-term debt of $26.17B, short-term debt of $1.79B and cash and equivalents of $1.95B.
MDT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts